PriceTargets.com logo

Perspective Therapeutics - CATX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 318.41%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.39 As of 12/4/2025 05:00 PM ET
▲ +0.18 (8.14%)

This chart shows the closing price for CATX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Perspective Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CATX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CATX

Analyst Price Target is $10.00
▲ +318.41% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Perspective Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 318.41% upside from the last price of $2.39.

This chart shows the closing price for CATX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Perspective Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2025Truist FinancialInitiated CoverageBuy$8.00 ➝ $12.00
11/21/2025UBS GroupLower TargetBuy ➝ Buy$18.00 ➝ $7.00
11/18/2025B. RileyLower TargetBuy ➝ Buy$12.00 ➝ $11.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Perspective Therapeutics logo
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.
Read More

Today's Range

Now: $2.39
Low: $2.17
High: $2.41

50 Day Range

MA: N/A

52 Week Range

Now: $2.39
Low: $1.60
High: $5.39

Volume

1,930,567 shs

Average Volume

1,082,639 shs

Market Capitalization

$177.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Perspective Therapeutics?

The following Wall Street analysts have issued stock ratings on Perspective Therapeutics in the last year: B. Riley, Truist Financial Corporation, and UBS Group AG.
View the latest analyst ratings for CATX.

What is the current price target for Perspective Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Perspective Therapeutics in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 318.4%. Truist Financial Corporation has the highest price target set, predicting CATX will reach $12.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $7.00 for Perspective Therapeutics in the next year.
View the latest price targets for CATX.

What is the current consensus analyst rating for Perspective Therapeutics?

Perspective Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CATX will outperform the market and that investors should add to their positions of Perspective Therapeutics.
View the latest ratings for CATX.

What other companies compete with Perspective Therapeutics?

Other companies that are similar to Perspective Therapeutics include CeriBell, Bioventus, Tactile Systems Technology, NeuroPace and Avanos Medical. Learn More about companies similar to Perspective Therapeutics.

How do I contact Perspective Therapeutics' investor relations team?

Perspective Therapeutics' physical mailing address is 2401 ELLIOTT AVENUE, SUITE 320, SEATTLE, WA, 98121. The company's listed phone number is (206) 676-0900. The official website for Perspective Therapeutics is isoray.com. Learn More about contacing Perspective Therapeutics investor relations.